1
|
Mecca C, Bertaglia V, Novello S. Third line scenario in advanced non-small cell lung cancer: is the anti-angiogenetic strategy the only actor up to now? Transl Cancer Res 2019; 8:S79-S83. [PMID: 35117068 PMCID: PMC8797454 DOI: 10.21037/tcr.2018.08.23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2018] [Accepted: 08/14/2018] [Indexed: 11/06/2022]
Affiliation(s)
- Caterina Mecca
- Oncology Department, San Luigi Hospital, University of Turin, Orbassano, TO, Italy
| | - Valentina Bertaglia
- Oncology Department, San Luigi Hospital, University of Turin, Orbassano, TO, Italy
| | - Silvia Novello
- Oncology Department, San Luigi Hospital, University of Turin, Orbassano, TO, Italy
| |
Collapse
|
2
|
Ponzetti A, Crsitiano C, Milanesi E, Ritorto G, Bustreo S, Mecca C, Ciuffreda L. Very elderly patients and lung cancer in a tertiary care center: a real life experience. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx426.035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
3
|
Ponzetti A, Zaccaria G, Bustreo S, Mecca C, Spadi R, Fanchini L, Ritorto G, Zanini M, Ciuffreda L, Racca P. Monocentric survey about the use of Raltitrexed in the daily clinical practice for patients with metastatic colorectal cancer. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw335.50] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
4
|
Tampellini M, Polverari RS, Ottone A, Alabiso I, Baratelli C, Bitossi R, Brizzi MP, Leone F, Forti L, Bertona E, Racca P, Mecca C, Alabiso O, Aglietta M, Berruti A, Scagliotti GV. Circannual variation of efficacy outcomes in patients with newly diagnosed metastatic colorectal cancer and treated with first-line chemotherapy. Chronobiol Int 2015; 32:1359-66. [PMID: 26540634 DOI: 10.3109/07420528.2015.1093495] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Seasonal variation of baseline diagnosis (or clinical suspect) of stage I-III colorectal cancer patients has been repeatedly reported as an independent variable influencing overall survival. However, data are conflicting and no information is available about such a rhythm in advanced stage patients. To test whether a circannual rhythm of efficacy outcomes can be detected in this setting, we collected data about response rate (RR), progression-free survival (PFS), and overall survival (OS) to first-line chemotherapy of 1610 newly diagnosed metastatic patients treated at four independent centers. Responses to first-line chemotherapy were available for 1495 patients. A strong circannual rhythm in RR was evident, with the higher proportion of responding patients in the subgroup diagnosed in January (acrophase). At the time of data cutoff, 1322 patients progressed and 986 died, with median PFS and OS of 11 and 25.6 months, respectively. A circannual rhythmicity of the proportion of patients progressing at 6 months and surviving at 1 year was demonstrated, with acrophases located both in winter (February and January, respectively), similar to what reported for RR. Several interpretations about the genesis of this cyclic variation could be claimed: the rhythm in sunlight exposure and, as a consequence, of vitamin D serum levels and folate degradation, the variability in toxic effect intensity of chemotherapy, and the rhythm in the biological behavior of tumor cells. This observation is worth of further investigation both in preclinical and in clinical settings in order to better elucidate the underlying mechanisms.
Collapse
Affiliation(s)
- M Tampellini
- a Department of Oncology , Division of Medical Oncology, San Luigi Hospital, University of Torino , Torino , Italy
| | - R S Polverari
- a Department of Oncology , Division of Medical Oncology, San Luigi Hospital, University of Torino , Torino , Italy
| | - A Ottone
- a Department of Oncology , Division of Medical Oncology, San Luigi Hospital, University of Torino , Torino , Italy
| | - I Alabiso
- a Department of Oncology , Division of Medical Oncology, San Luigi Hospital, University of Torino , Torino , Italy
| | - C Baratelli
- a Department of Oncology , Division of Medical Oncology, San Luigi Hospital, University of Torino , Torino , Italy
| | - R Bitossi
- a Department of Oncology , Division of Medical Oncology, San Luigi Hospital, University of Torino , Torino , Italy
| | - M P Brizzi
- a Department of Oncology , Division of Medical Oncology, San Luigi Hospital, University of Torino , Torino , Italy
| | - F Leone
- c Division of Medical Oncology at IRCCS Candiolo , Candiolo , Italy
| | - L Forti
- d Division of Medical Oncology , University of Oriental Piedmont , Novara , Italy , and
| | - E Bertona
- d Division of Medical Oncology , University of Oriental Piedmont , Novara , Italy , and
| | - P Racca
- e ColoRectal Cancer Unit , Oncologia 1, AOU Città della Salute , Torino
| | - C Mecca
- e ColoRectal Cancer Unit , Oncologia 1, AOU Città della Salute , Torino
| | - O Alabiso
- d Division of Medical Oncology , University of Oriental Piedmont , Novara , Italy , and
| | - M Aglietta
- c Division of Medical Oncology at IRCCS Candiolo , Candiolo , Italy
| | - A Berruti
- b Department of Medical and Surgical Specialties , Radiological Sciences and Public Health, Division of Medical Oncology, University of Brescia , Brescia , Italy
| | - G V Scagliotti
- a Department of Oncology , Division of Medical Oncology, San Luigi Hospital, University of Torino , Torino , Italy
| |
Collapse
|
5
|
Tampellini M, Ottone A, Alabiso I, Baratelli C, Bitossi R, Brizzi M, Leone F, Forti L, Bertona E, Racca P, Mecca C, Alabiso O, Aglietta M, Berruti A, Scagliotti G. Circannual variation of efficacy outcomes in patients with newly diagnosed metastatic colorectal cancer and treated with first-line chemotherapy. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv340.28] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
6
|
Pinta F, Ponzetti A, Spadi R, Fanchini L, Zanini M, Mecca C, Sonetto C, Ciuffreda L, Racca P. Pilot clinical trial on the efficacy of prophylactic use of vitamin K1-based cream (Vigorskin) to prevent cetuximab-induced skin rash in patients with metastatic colorectal cancer. Clin Colorectal Cancer 2013; 13:62-7. [PMID: 24332355 DOI: 10.1016/j.clcc.2013.10.001] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2013] [Revised: 09/27/2013] [Accepted: 10/02/2013] [Indexed: 12/20/2022]
Abstract
BACKGROUND Cetuximab is an effective option for the treatment of metastatic colorectal cancer in the first and subsequent lines of treatment; among its side effects, acneiform skin rash is one of the major causes of treatment delay, reduction, or interruption, with a negative effect on quality of life. No effective strategy to prevent skin rash induced by epidermal growth factor receptor inhibitors is available; however, encouraging results have come from vitamin K1, phytomenadione, applied as a topical formulation. Available studies have been conducted in heterogeneous populations and are mainly focused on the use of vitamin K1-based cream for the treatment, rather than the prophylaxis, of acneiform rash. PATIENTS AND METHODS Forty-one consecutive patients from a single center all affected by metastatic colorectal cancer and receiving cetuximab, alone or combined with chemotherapy, applied vitamin K1-based cream to prevent the occurrence of acneiform skin rash. The cream was applied twice a day on the face and trunk from the first day of administration of cetuximab. RESULTS The application of the cream was well tolerated. No grade 4 rash was reported. The proportion of grade 3 skin rash in the first 8 weeks of treatment in this population was 15%, at the lower limit of values reported in the literature, and the proportion of patients with grade 2 rash was reduced (22.5%). CONCLUSION This experience confirms available data in a homogeneous population, suggesting a possible benefit of topical vitamin K1 as prophylaxis for cetuximab-induced skin rash in patients with metastatic colorectal cancer.
Collapse
Affiliation(s)
- Francesco Pinta
- Colorectal Cancer Unit, Medical Oncology 1 Division, San Giovanni Battista Hospital, Turin, Italy
| | - Agostino Ponzetti
- Colorectal Cancer Unit, Medical Oncology 1 Division, San Giovanni Battista Hospital, Turin, Italy.
| | - Rosella Spadi
- Colorectal Cancer Unit, Medical Oncology 1 Division, San Giovanni Battista Hospital, Turin, Italy
| | - Laura Fanchini
- Colorectal Cancer Unit, Medical Oncology 1 Division, San Giovanni Battista Hospital, Turin, Italy
| | - Marcello Zanini
- Colorectal Cancer Unit, Medical Oncology 1 Division, San Giovanni Battista Hospital, Turin, Italy
| | - Caterina Mecca
- Colorectal Cancer Unit, Medical Oncology 1 Division, San Giovanni Battista Hospital, Turin, Italy
| | - Cristina Sonetto
- Colorectal Cancer Unit, Medical Oncology 1 Division, San Giovanni Battista Hospital, Turin, Italy
| | - Libero Ciuffreda
- Colorectal Cancer Unit, Medical Oncology 1 Division, San Giovanni Battista Hospital, Turin, Italy
| | - Patrizia Racca
- Colorectal Cancer Unit, Medical Oncology 1 Division, San Giovanni Battista Hospital, Turin, Italy
| |
Collapse
|
7
|
D'Amico L, Satolli MA, Mecca C, Castiglione A, Ceccarelli M, D'Amelio P, Garino M, De Giuli M, Sandrucci S, Ferracini R, Roato I. Bone metastases in gastric cancer follow a RANKL-independent mechanism. Oncol Rep 2013; 29:1453-8. [PMID: 23404437 DOI: 10.3892/or.2013.2280] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2012] [Accepted: 12/27/2012] [Indexed: 01/06/2023] Open
Abstract
Gastric cancer is one of the most common and lethal malignancies worldwide. Bone metastases in gastric cancer are less common than in other solid tumors, but when they occur the prognosis is generally poor. Increased osteoclastogenesis and osteoclast activity are common features in bone metastases caused by different osteotropic cancer. We investigated osteoclastogenesis and its mechanisms in gastric cancer by enrolling 31 newly diagnosed gastric cancer patients and 45 healthy controls. We studied in vitro osteoclastogenesis in the peripheral blood mononuclear cell cultures of patients and controls, showing spontaneous osteoclastogenesis for half of the patients. This osteoclastogenesis was RANKL- and TNF-α-independent. We analyzed primary tumor and bone metastatic tissues of gastric cancer for the expression of genes involved in osteoclastogenesis. The expression of transforming growth factor-β (TGF-β), osteoprotegerin (OPG), IL-7 and dickkopf-1 (DKK-1) was higher in primary tumors than in bone metastases. RANKL was not detectable in primary tumor or in bone metastatic tissue. The serum RANKL level was significantly higher in healthy controls than in patients, and it was not related to osteoclastogenesis, thereby suggesting that RANKL is not involved in the bone metastatic mechanisms in gastric cancer. We hypothesized a role of RANKL in angiogenesis, thus we compared the serum levels of RANKL to those of VEGF, since VEGF is directly related to angiogenesis. Different from RANKL, the VEGF serum levels were higher in gastric patients than in controls, suggesting a block of the angiogenesis inhibition due to RANKL. RANKL and VEGF serum levels were not predictive of overall survival in our cohort of gastric patients.
Collapse
Affiliation(s)
- Lucia D'Amico
- CeRMS (Center for Experimental Research and Medical Studies), Department of Medical Oncology, San Giovanni Battista Hospital, and Department of Surgical and Medical Discplines, University of Turin, Turin, Italy
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Evangelista W, Satolli M, Napoletano R, Giacobino A, Novarino A, Mecca C, Brusa F, Pomba L, Garino M, Ciuffreda L, Fronda G. Characteristics of patients with gastric cancer who had undergone curative surgery: A 15-year monoistitutional experience. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e14526] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
9
|
Satolli M, Evangelista W, Mecca C, Napoletano R, Giacobino A, Novarino A, Brusa F, Fiore J, Pomba L, Garino M, Fronda G, Ciuffreda L. Utility of routine endoscopy in the follow-up of resected gastric carcinoma. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|